Biotech Beach Bum

Regulus’s new microRNA blocker technology (aka anti-MIR) hits its first milestone for marketing/funding partner GSK. This promising approach delivers small pieces of RNA into cells to block transcription and thereby slow gene expression.
 
http://www.xconomy.com/san-diego/2009/05/14/regulus-hits-gsk-milestone/